167 related articles for article (PubMed ID: 29785351)
1. Genetic inactivation of alpha-synuclein affects embryonic development of dopaminergic neurons of the substantia nigra, but not the ventral tegmental area, in mouse brain.
Tarasova TV; Lytkina OA; Goloborshcheva VV; Skuratovskaya LN; Antohin AI; Ovchinnikov RK; Kukharsky MS
PeerJ; 2018; 6():e4779. PubMed ID: 29785351
[TBL] [Abstract][Full Text] [Related]
2. The new line of genetically modified mice with constitutive knockout of the gene alpha synuclein to study pathogenetic aspects of differential loss of dopaminergic neurons .
Tarasova TV; Ustyugov AA; Ninkina NN; Skvortsova VI
Patol Fiziol Eksp Ter; 2016; 60(3):4-9. PubMed ID: 29243900
[TBL] [Abstract][Full Text] [Related]
3. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
4. Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson's disease.
Lv Z; Jiang H; Xu H; Song N; Xie J
J Neural Transm (Vienna); 2011 Mar; 118(3):361-9. PubMed ID: 20556443
[TBL] [Abstract][Full Text] [Related]
5. Selective increase of in vivo firing frequencies in DA SN neurons after proteasome inhibition in the ventral midbrain.
Subramaniam M; Kern B; Vogel S; Klose V; Schneider G; Roeper J
Eur J Neurosci; 2014 Sep; 40(6):2898-909. PubMed ID: 25059097
[TBL] [Abstract][Full Text] [Related]
6. The role of alpha-synuclein in the development of the dopaminergic neurons in the substantia nigra and ventral tegmental area.
Tarasova TV; Lytkina OA; Roman AY; Bachurin SO; Ustyugov AA
Dokl Biol Sci; 2016; 466():5-7. PubMed ID: 27021360
[TBL] [Abstract][Full Text] [Related]
7. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons.
Mosharov EV; Larsen KE; Kanter E; Phillips KA; Wilson K; Schmitz Y; Krantz DE; Kobayashi K; Edwards RH; Sulzer D
Neuron; 2009 Apr; 62(2):218-29. PubMed ID: 19409267
[TBL] [Abstract][Full Text] [Related]
8. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
Maingay M; Romero-Ramos M; Carta M; Kirik D
Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
[TBL] [Abstract][Full Text] [Related]
9. Aquaporin-4 deficiency diminishes the differential degeneration of midbrain dopaminergic neurons in experimental Parkinson's disease.
Zhang J; Yang B; Sun H; Zhou Y; Liu M; Ding J; Fang F; Fan Y; Hu G
Neurosci Lett; 2016 Feb; 614():7-15. PubMed ID: 26748031
[TBL] [Abstract][Full Text] [Related]
10. Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats.
Yu Z; Xu X; Xiang Z; Zhou J; Zhang Z; Hu C; He C
PLoS One; 2010 Apr; 5(4):e9956. PubMed ID: 20386702
[TBL] [Abstract][Full Text] [Related]
11. 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis.
Burke WJ; Li SW; Williams EA; Nonneman R; Zahm DS
Brain Res; 2003 Nov; 989(2):205-13. PubMed ID: 14556942
[TBL] [Abstract][Full Text] [Related]
12. Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease.
Alarcón-Arís D; Recasens A; Galofré M; Carballo-Carbajal I; Zacchi N; Ruiz-Bronchal E; Pavia-Collado R; Chica R; Ferrés-Coy A; Santos M; Revilla R; Montefeltro A; Fariñas I; Artigas F; Vila M; Bortolozzi A
Mol Ther; 2018 Feb; 26(2):550-567. PubMed ID: 29273501
[TBL] [Abstract][Full Text] [Related]
13. α-Synuclein-Dependent Calcium Entry Underlies Differential Sensitivity of Cultured SN and VTA Dopaminergic Neurons to a Parkinsonian Neurotoxin.
Lieberman OJ; Choi SJ; Kanter E; Saverchenko A; Frier MD; Fiore GM; Wu M; Kondapalli J; Zampese E; Surmeier DJ; Sulzer D; Mosharov EV
eNeuro; 2017; 4(6):. PubMed ID: 29177188
[TBL] [Abstract][Full Text] [Related]
14. Emotional memory impairments induced by AAV-mediated overexpression of human α-synuclein in dopaminergic neurons of the ventral tegmental area.
Alvarsson A; Caudal D; Björklund A; Svenningsson P
Behav Brain Res; 2016 Jan; 296():129-133. PubMed ID: 26341317
[TBL] [Abstract][Full Text] [Related]
15. Mutant α-synuclein enhances firing frequencies in dopamine substantia nigra neurons by oxidative impairment of A-type potassium channels.
Subramaniam M; Althof D; Gispert S; Schwenk J; Auburger G; Kulik A; Fakler B; Roeper J
J Neurosci; 2014 Oct; 34(41):13586-99. PubMed ID: 25297088
[TBL] [Abstract][Full Text] [Related]
16. Regional microglia are transcriptionally distinct but similarly exacerbate neurodegeneration in a culture model of Parkinson's disease.
Kostuk EW; Cai J; Iacovitti L
J Neuroinflammation; 2018 May; 15(1):139. PubMed ID: 29751760
[TBL] [Abstract][Full Text] [Related]
17. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.
Vila M; Vukosavic S; Jackson-Lewis V; Neystat M; Jakowec M; Przedborski S
J Neurochem; 2000 Feb; 74(2):721-9. PubMed ID: 10646524
[TBL] [Abstract][Full Text] [Related]
18. Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra.
von Bohlen und Halbach O; Minichiello L; Unsicker K
FASEB J; 2005 Oct; 19(12):1740-2. PubMed ID: 16037097
[TBL] [Abstract][Full Text] [Related]
19. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice.
Robertson DC; Schmidt O; Ninkina N; Jones PA; Sharkey J; Buchman VL
J Neurochem; 2004 Jun; 89(5):1126-36. PubMed ID: 15147505
[TBL] [Abstract][Full Text] [Related]
20. Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease.
Liang CL; Wang TT; Luby-Phelps K; German DC
Exp Neurol; 2007 Feb; 203(2):370-80. PubMed ID: 17010972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
